Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total Kite Cell Therapy Product Sales by Year
Total Kite Cell Therapy Product Sales ($M) ($M)
Gilead Sciences Total Kite Cell Therapy Product Sales: $1,839M in FY2025, down 6.8% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-24) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Kite Cell Therapy Product Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,839 | -6.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1,973 | +5.6% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 1,869 | +28.1% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 1,459 | +67.5% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 871 | +43.5% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 607 | +33.1% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 456 | +72.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 264 | – | Form 10-K (filed 2021-02-25) ↗ |
Breakdown
What makes up total Kite Cell Therapy Product Sales
- Total Kite Cell Therapy Product Sales — U.S. sales ($M)748 · FY2025
- Total Kite Cell Therapy Product Sales — Europe sales ($M)755 · FY2025
- Total Kite Cell Therapy Product Sales — Rest of World sales ($M)335 · FY2025
- Yescarta (axicabtagene ciloleucel — LBCL / FL CAR T) ($M)1,495 · FY2025
- Tecartus (brexucabtagene autoleucel — MCL / ALL CAR T) ($M)344 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Total Kite Cell Therapy Product Sales ($M), annual FY2018–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/onc-cell-therapy
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.